SCHEMBL135647

SCHEMBL135647

Cc1nc2sc3c(c2c(-c2ccccc2)c1CC(=O)O)CCC(C)C3

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.64
CNR1 P21554 1/20 0.48
CNR2 P34972 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
CSNK2A2 P19784 2/20 0.45
CSNK2B P67870 2/20 0.45
CSNK2A1 P68400 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 3/20 0.45
BRD4 O60885 3/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
FGFR1 P11362 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL135409 0.91 KMT2A (0.59) KMT2ACNR1CNR2GPR55CSNK2A2
SCHEMBL136926 0.85 KMT2A (0.52) KMT2ACNR1CNR2GPR55SMN1; SMN2
SCHEMBL99096 0.85 KMT2A (0.82) KMT2A
SCHEMBL99417 0.78 KMT2A (0.96) KMT2A
SCHEMBL135072 0.78 KMT2A (1.00) KMT2A
SCHEMBL142032 0.77 KMT2A (0.78) KMT2A
SCHEMBL3477489 0.76 KMT2A (0.84) KMT2A
SCHEMBL3476305 0.76 KMT2A (0.84) KMT2A
SCHEMBL132834 0.76 KMT2A (0.84) KMT2A
SCHEMBL139375 0.76 KMT2A (0.81) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12465604-B2 Functional cure of retroviral infection KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-11-11 US claimed
US-20140296272-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS CISTIM LEUVEN VZW (BE) 2014-10-02 US claimed
EP-2430029-A1 THIENO [2, 3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS Katholieke Universiteit Leuven (BE) 2012-03-21 EP claimed
US-20120059028-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2012-03-08 US claimed
WO-2010130842-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2010-11-18 WO claimed
US-12465604-B2 Functional cure of retroviral infection KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-11-11 US disclosed
EP-2430029-B1 THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS UNIV LEUVEN KATH (BE) 2018-01-10 EP disclosed
US-8785638-B2 Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2014-07-22 US disclosed
US-20120059028-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12465604-B2 Functional cure of retroviral infection HDLBP, VSIG8, TNFSF11 KMT2A 2356/4885CNR1 4229/4885CNR2 4484/4885
US-20140296272-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS TYMP, DUT, MAVS KMT2A 2903/4885CNR1 1716/4885CNR2 1919/4885
US-20120059028-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS TYMP, DUT, MAVS KMT2A 2903/4885CNR1 1716/4885CNR2 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.